MEI Pharma, Inc. (MEIP)
-NasdaqCM | Prev Close: | 8.92 |
|---|
| Open: | N/A |
|---|
| Bid: | 3.50 x 600 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 13.50 |
|---|
| Beta: | 1.56 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.98 - 13.20 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 85,546 |
|---|
| Market Cap: | 152.67M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MEI PHARMA, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- 8 Stocks Under $10 Trending Sharply Higherat TheStreet(Tue, May 14)
- MEI PHARMA, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- MEI Pharma CEO To Present At Needham Healthcare ConferencePR Newswire(Tue, Apr 23)
- 5 Health Care Stocks Under $10 Ready to Rip Higherat TheStreet(Thu, Apr 18)
- MEI Pharma initiated with a Buy at Stifelat theflyonthewall.com(Mon, Apr 15)
- Coverage initiated on MEI Pharma. by StifelBriefing.com(Mon, Apr 15)
- 5 Stocks Under $10 Set to Soar Higherat TheStreet(Thu, Apr 11)
- 4 Healthcare Stock Stories for Thursday Investment Wellnessat Wall St. Cheat Sheet(Thu, Apr 11)
- MEI Pharma's Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth In Recurrent Ovarian Cancer ModelPR Newswire(Wed, Apr 10)
- MEI PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 10)
- MEI Pharma Announces $15.2 Million Registered Offering Of Common StockPR Newswire(Fri, Apr 5)
- MEI PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Apr 4)
- MEI PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendment or Waiver to Code of EthicsEDGAR Online(Fri, Mar 29)
- MEI Pharma's CEO Hosts Annual Stockholders Meeting (Transcript)at Seeking Alpha(Tue, Mar 26)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| MEIP | 0.00% | 152.67M |
| NVO | 0.00% | 93.15B |
| TEVA | 0.00% | 34.28B |
| AGN | 0.00% | 30.06B |
| FRX | 0.00% | 10.26B |
Key Statistics
| Forward P/E (1 yr): | 63.71 |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -1.52 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patie...
View More 
0.80%